The deal closure removes execution risk but the $70M cash outlay pressures near-term liquidity. Monitor Rigel's upcoming 10-Q for cash runway and initial VEPPANU revenue ramp. Milestone triggers and royalty start dates will be key catalysts.
Price Chart
Executive Summary
Rigel Pharmaceuticals completed its previously announced exclusive global license agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), an FDA-approved ER+/HER2- breast cancer treatment. The deal closed following HSR clearance, with Rigel paying the $70 million upfront cash consideration. This milestone de-risks the transaction but provides no new financial terms beyond the original announcement.
Key Facts
- License agreement with Arvinas/Pfizer for VEPPANU (vepdegestrant) became effective on June 11, 2026.
- Company paid a one-time upfront payment of $70.0 million to the licensors upon closing.
- HSR waiting period terminated early and all other closing conditions satisfied.
- Rigel granted exclusive global rights to develop, manufacture and commercialize VEPPANU.
Financial Impact
$70.0 million upfront cash payment (approximately 11.6% of $601M market cap); additional contingent milestones up to $320M plus royalties and up to $40M development cost reimbursement per prior disclosure.
Risk Factors
- Significant upfront cash payment may strain balance sheet if VEPPANU revenue ramp is slow.
- Milestone payments and development cost reimbursements create future cash obligations beyond the upfront.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001034842-26-000043 |
| Document: 0001034842-26-000043-index.html | 0001034842-26-000043 |
| Document: 0001034842-26-000043.txt | 0001034842-26-000043 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $40.48 $49.42 | ▲ +22.09% | ▲ +22.69% | $46.50 (+14.87%) |
Jun 17, 2026 15w ago | 8-K | $32.91 $41.67 | ▲ +26.62% | ▲ +26.09% | $46.50 (+41.29%) |
Jun 11, 2026 16w ago | Institutional Cluster | $32.08 $43.76 | ▲ +36.41% | ▲ +34.52% | $46.50 (+44.95%) |
May 20, 2026 19w ago | 8-K | $29.19 $35.78 | ▲ +22.58% | ▲ +22.24% | $46.50 (+59.30%) |
May 12, 2026 20w ago | 8-K | $32.13 $32.08 | ▼ −0.16% | ▲ +0.46% | $46.50 (+44.72%) |
May 5, 2026 21w ago | 8-K | $26.67 $30.30 | ▼ −13.61% | ▼ −10.83% | $46.50 (−74.35%) |
Apr 21, 2026 23w ago | 8-K | $30.47 $28.30 | ▲ +7.12% | ▲ +10.29% | $46.50 (−52.61%) |
Apr 3, 2026 25w ago | DEFA14A | $27.36 $29.54 | ▲ +7.97% | ▼ −1.01% | $46.50 (+69.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access